Skip to main content
Top
Published in: Fibrogenesis & Tissue Repair 1/2012

Open Access 01-12-2012 | Research

Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis

Authors: Chris J Watson, Dermot Phelan, Maojia Xu, Patrick Collier, Roisin Neary, Albert Smolenski, Mark Ledwidge, Kenneth McDonald, John Baugh

Published in: Fibrogenesis & Tissue Repair | Issue 1/2012

Login to get access

Abstract

Background

Mechanical overload of the heart is associated with excessive deposition of extracellular matrix proteins and the development of cardiac fibrosis. This can result in reduced ventricular compliance, diastolic dysfunction, and heart failure. Extracellular matrix synthesis is regulated primarily by cardiac fibroblasts, more specifically, the active myofibroblast. The influence of mechanical stretch on human cardiac fibroblasts’ response to pro-fibrotic stimuli, such as transforming growth factor beta (TGFβ), is unknown as is the impact of stretch on B-type natriuretic peptide (BNP) and natriuretic peptide receptor A (NPRA) expression. BNP, acting via NPRA, has been shown to play a role in modulation of cardiac fibrosis.

Methods and results

The effect of cyclical mechanical stretch on TGFβ induction of myofibroblast differentiation in primary human cardiac fibroblasts and whether differences in response to stretch were associated with changes in the natriuretic peptide system were investigated. Cyclical mechanical stretch attenuated the effectiveness of TGFβ in inducing myofibroblast differentiation. This finding was associated with a novel observation that mechanical stretch can increase BNP and NPRA expression in human cardiac fibroblasts, which could have important implications in modulating myocardial fibrosis. Exogenous BNP treatment further reduced the potency of TGFβ on mechanically stretched fibroblasts.

Conclusion

We postulate that stretch induced up-regulation of the natriuretic peptide system may contribute to the observed reduction in myofibroblast differentiation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, Weber KT: Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr. 1997, 10: 657-664. 10.1016/S0894-7317(97)70028-2.CrossRefPubMed Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, Weber KT: Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr. 1997, 10: 657-664. 10.1016/S0894-7317(97)70028-2.CrossRefPubMed
2.
go back to reference Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998, 16: 1031-1041. 10.1097/00004872-199816070-00018.CrossRefPubMed Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998, 16: 1031-1041. 10.1097/00004872-199816070-00018.CrossRefPubMed
3.
go back to reference Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000, 101: 1729-1735. 10.1161/01.CIR.101.14.1729.CrossRefPubMed Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000, 101: 1729-1735. 10.1161/01.CIR.101.14.1729.CrossRefPubMed
4.
go back to reference Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002, 105: 2512-2517. 10.1161/01.CIR.0000017264.66561.3D.CrossRefPubMed Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002, 105: 2512-2517. 10.1161/01.CIR.0000017264.66561.3D.CrossRefPubMed
5.
go back to reference Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000, 102: 1388-1393. 10.1161/01.CIR.102.12.1388.CrossRefPubMed Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000, 102: 1388-1393. 10.1161/01.CIR.102.12.1388.CrossRefPubMed
6.
go back to reference Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993, 27: 341-348. 10.1093/cvr/27.3.341.CrossRefPubMed Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993, 27: 341-348. 10.1093/cvr/27.3.341.CrossRefPubMed
7.
go back to reference Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A: Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004, 110: 552-557. 10.1161/01.CIR.0000137118.47943.5C.CrossRefPubMed Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A: Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004, 110: 552-557. 10.1161/01.CIR.0000137118.47943.5C.CrossRefPubMed
8.
go back to reference Brilla CG, Rupp H, Maisch B: Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz. 2003, 28: 744-753. 10.1007/s00059-003-2524-6.CrossRefPubMed Brilla CG, Rupp H, Maisch B: Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz. 2003, 28: 744-753. 10.1007/s00059-003-2524-6.CrossRefPubMed
9.
go back to reference van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J: Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010, 7: 30-37. 10.1038/nrcardio.2009.199.CrossRefPubMed van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J: Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010, 7: 30-37. 10.1038/nrcardio.2009.199.CrossRefPubMed
10.
go back to reference Nishikimi T, Maeda N, Matsuoka H: The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006, 69: 318-328. 10.1016/j.cardiores.2005.10.001.CrossRefPubMed Nishikimi T, Maeda N, Matsuoka H: The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006, 69: 318-328. 10.1016/j.cardiores.2005.10.001.CrossRefPubMed
11.
go back to reference Blaauw E, van Nieuwenhoven FA, Willemsen P, Delhaas T, Prinzen FW, Snoeckx LH, van Bilsen M, van der Vusse GJ: Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol. 2010, 299: H780-H787. 10.1152/ajpheart.00822.2009.CrossRefPubMed Blaauw E, van Nieuwenhoven FA, Willemsen P, Delhaas T, Prinzen FW, Snoeckx LH, van Bilsen M, van der Vusse GJ: Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol. 2010, 299: H780-H787. 10.1152/ajpheart.00822.2009.CrossRefPubMed
12.
go back to reference Christoffersen TE, Aplin M, Strom CC, Sheikh SP, Skott O, Busk PK, Haunso S, Nielsen LB: Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006, 290: H1635-H1641.CrossRefPubMed Christoffersen TE, Aplin M, Strom CC, Sheikh SP, Skott O, Busk PK, Haunso S, Nielsen LB: Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006, 290: H1635-H1641.CrossRefPubMed
13.
go back to reference Kapoun AM, Liang F, O’Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004, 94: 453-461. 10.1161/01.RES.0000117070.86556.9F.CrossRefPubMed Kapoun AM, Liang F, O’Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004, 94: 453-461. 10.1161/01.RES.0000117070.86556.9F.CrossRefPubMed
14.
go back to reference Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H: Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept. 2009, 154: 44-53. 10.1016/j.regpep.2009.02.006.CrossRefPubMed Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H: Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept. 2009, 154: 44-53. 10.1016/j.regpep.2009.02.006.CrossRefPubMed
15.
go back to reference Lijnen P, Petrov V: Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol. 2002, 24: 333-344. 10.1358/mf.2002.24.6.693065.CrossRefPubMed Lijnen P, Petrov V: Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol. 2002, 24: 333-344. 10.1358/mf.2002.24.6.693065.CrossRefPubMed
16.
go back to reference Lijnen PJ, Petrov VV, Fagard RH: Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab. 2000, 71: 418-435. 10.1006/mgme.2000.3032.CrossRefPubMed Lijnen PJ, Petrov VV, Fagard RH: Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab. 2000, 71: 418-435. 10.1006/mgme.2000.3032.CrossRefPubMed
17.
go back to reference Bujak M, Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007, 74: 184-195. 10.1016/j.cardiores.2006.10.002.PubMedCentralCrossRefPubMed Bujak M, Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007, 74: 184-195. 10.1016/j.cardiores.2006.10.002.PubMedCentralCrossRefPubMed
18.
go back to reference Vaughan MB, Howard EW, Tomasek JJ: Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res. 2000, 257: 180-189. 10.1006/excr.2000.4869.CrossRefPubMed Vaughan MB, Howard EW, Tomasek JJ: Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res. 2000, 257: 180-189. 10.1006/excr.2000.4869.CrossRefPubMed
19.
go back to reference Merryman WD, Lukoff HD, Long RA, Engelmayr GC, Hopkins RA, Sacks MS: Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol. 2007, 16: 268-276. 10.1016/j.carpath.2007.03.006.PubMedCentralCrossRefPubMed Merryman WD, Lukoff HD, Long RA, Engelmayr GC, Hopkins RA, Sacks MS: Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol. 2007, 16: 268-276. 10.1016/j.carpath.2007.03.006.PubMedCentralCrossRefPubMed
20.
go back to reference Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S: Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem. 1992, 267: 10551-10560.PubMed Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S: Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem. 1992, 267: 10551-10560.PubMed
21.
go back to reference Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3: 349-363. 10.1038/nrm809.CrossRefPubMed Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3: 349-363. 10.1038/nrm809.CrossRefPubMed
22.
go back to reference Blaauboer ME, Smit TH, Hanemaaijer R, Stoop R, Everts V: Cyclic mechanical stretch reduces myofibroblast differentiation of primary lung fibroblasts. BiochemBiophys Res Commun. 2011, 404: 23-27. 10.1016/j.bbrc.2010.11.033.CrossRef Blaauboer ME, Smit TH, Hanemaaijer R, Stoop R, Everts V: Cyclic mechanical stretch reduces myofibroblast differentiation of primary lung fibroblasts. BiochemBiophys Res Commun. 2011, 404: 23-27. 10.1016/j.bbrc.2010.11.033.CrossRef
23.
go back to reference Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C: Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011, 4: 44-52. 10.1161/CIRCHEARTFAILURE.109.931451.CrossRefPubMed Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C: Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011, 4: 44-52. 10.1161/CIRCHEARTFAILURE.109.931451.CrossRefPubMed
24.
go back to reference Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T: Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension. 2004, 43: 739-745. 10.1161/01.HYP.0000118584.33350.7d.CrossRefPubMed Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T: Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension. 2004, 43: 739-745. 10.1161/01.HYP.0000118584.33350.7d.CrossRefPubMed
25.
go back to reference Takahashi N, Calderone A, Izzo NJ, Maki TM, Marsh JD, Colucci WS: Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest. 1994, 94: 1470-1476. 10.1172/JCI117485.PubMedCentralCrossRefPubMed Takahashi N, Calderone A, Izzo NJ, Maki TM, Marsh JD, Colucci WS: Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest. 1994, 94: 1470-1476. 10.1172/JCI117485.PubMedCentralCrossRefPubMed
26.
go back to reference Shiota N, Rysa J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA: A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens. 2003, 21: 1935-1944. 10.1097/00004872-200310000-00022.CrossRefPubMed Shiota N, Rysa J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA: A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens. 2003, 21: 1935-1944. 10.1097/00004872-200310000-00022.CrossRefPubMed
27.
go back to reference Syedain ZH, Tranquillo RT: TGF-beta1 diminishes collagen production during long-term cyclic stretching of engineered connective tissue: implication of decreased ERK signaling. J Biomech. 2011, 44: 848-855. 10.1016/j.jbiomech.2010.12.007.PubMedCentralCrossRefPubMed Syedain ZH, Tranquillo RT: TGF-beta1 diminishes collagen production during long-term cyclic stretching of engineered connective tissue: implication of decreased ERK signaling. J Biomech. 2011, 44: 848-855. 10.1016/j.jbiomech.2010.12.007.PubMedCentralCrossRefPubMed
28.
go back to reference Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC: Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002, 91: 1127-1134. 10.1161/01.RES.0000046234.73401.70.CrossRefPubMed Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC: Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002, 91: 1127-1134. 10.1161/01.RES.0000046234.73401.70.CrossRefPubMed
29.
go back to reference Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC: BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006, 209: 943-949. 10.1002/jcp.20793.CrossRefPubMed Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC: BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006, 209: 943-949. 10.1002/jcp.20793.CrossRefPubMed
30.
go back to reference Jarvis MD, Rademaker MT, Ellmers LJ, Currie MJ, McKenzie JL, Palmer BR, Frampton CM, Richards AM, Cameron VA: Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles. Am J Physiol Heart Circ Physiol. 2006, 291: H1952-H1958. 10.1152/ajpheart.00764.2005.CrossRefPubMed Jarvis MD, Rademaker MT, Ellmers LJ, Currie MJ, McKenzie JL, Palmer BR, Frampton CM, Richards AM, Cameron VA: Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles. Am J Physiol Heart Circ Physiol. 2006, 291: H1952-H1958. 10.1152/ajpheart.00764.2005.CrossRefPubMed
31.
go back to reference Koivisto E, Karkkola L, Majalahti T, Aro J, Tokola H, Kerkela R, Ruskoaho H: M-CAT element mediates mechanical stretch-activated transcription of B-type natriuretic peptide via ERK activation. Can J Physiol Pharmacol. 2011, 89: 539-550. 10.1139/y11-049.CrossRefPubMed Koivisto E, Karkkola L, Majalahti T, Aro J, Tokola H, Kerkela R, Ruskoaho H: M-CAT element mediates mechanical stretch-activated transcription of B-type natriuretic peptide via ERK activation. Can J Physiol Pharmacol. 2011, 89: 539-550. 10.1139/y11-049.CrossRefPubMed
32.
go back to reference Gan Q, Yoshida T, Li J, Owens GK: Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res. 2007, 101: 883-892. 10.1161/CIRCRESAHA.107.154831.CrossRefPubMed Gan Q, Yoshida T, Li J, Owens GK: Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res. 2007, 101: 883-892. 10.1161/CIRCRESAHA.107.154831.CrossRefPubMed
33.
go back to reference Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003, 200: 500-503. 10.1002/path.1427.CrossRefPubMed Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003, 200: 500-503. 10.1002/path.1427.CrossRefPubMed
34.
go back to reference Dalla Costa AP, Clemente CF, Carvalho HF, Carvalheira JB, Nadruz W, Franchini KG: FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex. Cardiovasc Res. 2010, 86: 421-431. 10.1093/cvr/cvp416.CrossRefPubMed Dalla Costa AP, Clemente CF, Carvalho HF, Carvalheira JB, Nadruz W, Franchini KG: FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex. Cardiovasc Res. 2010, 86: 421-431. 10.1093/cvr/cvp416.CrossRefPubMed
35.
go back to reference Atance J, Yost MJ, Carver W: Influence of the extracellular matrix on the regulation of cardiac fibroblast behavior by mechanical stretch. J Cell Physiol. 2004, 200: 377-386. 10.1002/jcp.20034.CrossRefPubMed Atance J, Yost MJ, Carver W: Influence of the extracellular matrix on the regulation of cardiac fibroblast behavior by mechanical stretch. J Cell Physiol. 2004, 200: 377-386. 10.1002/jcp.20034.CrossRefPubMed
36.
go back to reference Huntley BK, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC: B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J Cell Physiol. 2010, 225: 251-255. 10.1002/jcp.22253.CrossRefPubMed Huntley BK, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC: B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J Cell Physiol. 2010, 225: 251-255. 10.1002/jcp.22253.CrossRefPubMed
Metadata
Title
Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis
Authors
Chris J Watson
Dermot Phelan
Maojia Xu
Patrick Collier
Roisin Neary
Albert Smolenski
Mark Ledwidge
Kenneth McDonald
John Baugh
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue 1/2012
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-5-9

Other articles of this Issue 1/2012

Fibrogenesis & Tissue Repair 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine